Details

Autor(en) / Beteiligte

• White, K.
• Connor, K.
• Clerkin, J.
• Murphy, B.M.
• Salvucci, M.
• O'Farrell, A.C.
• Rehm, M.
• O'Brien, D.
• Prehn, J.H.M.
• Niclou, S.P.
• Lamfers, M.L.M.
• Verreault, M.
• Idbaih, A.
• Verhaak, R.
• Golebiewska, A.
• Byrne, A.T.

Titel

New hints towards a precision medicine strategy for IDH wild-type glioblastoma

Ist Teil von

• Annals of oncology, 2020-12, Vol.31 (12), p.1679-1692

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the subtyping effort in the IDH-wild-type setting may provide directions for future precision therapies. Here, we review recent learnings in the field, and further consider how tumour microenvironment differences across subtypes may reveal novel contexts of vulnerability. We discuss recent treatment approaches and ongoing trials in the IDH-wild-type glioblastoma setting, and propose an integrated discovery stratagem incorporating multi-omics, single-cell technologies and computational approaches. •Studying IDH-wt GBM subtype specific differences across the TME may reveal novel contexts of vulnerability.•Knowledge gained from diverse molecular profiling should direct future targeted therapeutic strategies.•Stratifying patients based on immune contexture may guide novel immune therapy approaches for IDH-wt patients.•Due to the heterogeneous nature of GBM, future trials should consider a stratified, ‘subtype-specific’ design.•We propose an integrated multi-omic discovery strategy to establish improved precision targeting in the IDH-wt GBM setting